Sodium phosphate enema, oral rifaximin and polyethylene glycol ( DrugBank: Rifaximin, Polyethylene glycol, Phosphate )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 6 | パーキンソン病 | 1 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04730245 (ClinicalTrials.gov) | June 1, 2018 | 25/1/2021 | Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease | Targeting Gut Microbiota for Motor Complications in Parkinson´s Disease | Parkinson's Disease Aggravated | Drug: sodium phosphate enema, oral rifaximin and polyethylene glycol | Torre Médica Santé | NULL | Completed | 18 Years | N/A | All | 14 | Phase 1 | Mexico |